Brimonidine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Brimonidine
Brimonidine: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Brimonidine, so there is currently no new predicted indication. The drug’s own recorded uses are listed below. They are not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 5 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| glaucoma | licence in another country |
| ocular hypertension | licence in another country |
| open-angle glaucoma | licence in another country |
| skin diseases | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| rosacea |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 14496Y | Alphagan P 1.5 | Eye drops containing brimonidine tartrat | Valid |
Safety Considerations
- Disease associations flagged as contraindications in the knowledge graph (these are not taken from the label text): multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, anxiety and related mood disorders (neurotic disorder, dysthymic disorder), diabetes mellitus, diabetic ketoacidosis, hypoglycaemia, myasthenia gravis and other neuromuscular junction disease, hyperthyroidism (Graves disease, thyrotoxicosis), atrioventricular block, cerebrovascular disorder, pulmonary emphysema and bronchial disease, Raynaud disease, thromboangiitis obliterans, and anaphylaxis.
- Drug interactions: The interaction query returned 100 records, all with an unclassified severity level. Examples include atropine, metformin, glimepiride, rosiglitazone, prednisone, simvastatin and several proton pump inhibitors. Clinical significance has not been graded, so these should be checked against the Product Information.
- Paediatric caution: Brimonidine is associated with CNS depression and apnoea risk in neonates and infants. This is directly relevant to any hereditary or congenital paediatric glaucoma use.
Please refer to the TGA-approved Product Information (PI) for label warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.